Related Experiment Video
Updated: Aug 18, 2026
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong
J Chau1, B M Cheung, S M McGhee
1Department of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong.
Insights
Secondary prevention with pravastatin is a cost-effective strategy for Hong Kong patients with coronary heart disease. This analysis of the CARE study provides key cost per quality-adjusted life year gained figures for healthcare resource allocation.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Coronary heart disease (CHD) poses a significant burden on healthcare systems.
- Secondary prevention strategies are crucial for managing patients post-myocardial infarction (MI).
- Pravastatin has demonstrated efficacy in reducing cardiovascular events.
Purpose of the Study:
- To evaluate the cost-effectiveness of pravastatin for secondary prevention in Hong Kong patients with CHD.
- To determine the cost per quality-adjusted life year (QALY) gained from pravastatin therapy.
- To inform healthcare resource allocation decisions for CHD management in Hong Kong.
Main Methods:
- Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed.
- Data were based on published results from the Pravastatin Pooling Project (CARE study).
- Analyses included costs per life saved, event prevention, procedure prevention, and QALY gained.
Main Results:
- The cost per life saved was HK$4,442,350.
- The cost per fatal or non-fatal cardiac event prevented was HK$1,146,413.
- Net cost per QALY gained was HK$73,218 and HK$65,280 using two models.
Conclusions:
- Pravastatin therapy for secondary prevention in CHD patients is a potentially cost-effective intervention in Hong Kong.
- Findings can guide healthcare resource prioritization for CHD.
- Results should be considered alongside alternative CHD interventions.
Objective:
To determine the cost-effectiveness of secondary prevention with pravastatin in Hong Kong patients with coronary heart disease and average cholesterol levels.
Design:
Cost-effectiveness analysis based on published results of the CARE study.
Patients:
Men and women post-myocardial infarction with average cholesterol levels.
Main Outcome Measures:
Cost-effectiveness analysis: cost per life saved, cost per fatal or non-fatal coronary event prevented, cost per procedure prevented, and cost per fatal or non-fatal stroke prevented. Cost-utility analysis: gross cost and net cost per quality-adjusted life year gained calculated using two alternative models.
Results:
Cost per life saved or death prevented was HK$4,442,350 (non-discounted); cost per fatal or non-fatal cardiac event prevented HK$1,146,413; cost per procedure prevented HK$732,759; and cost per fatal or non-fatal stroke prevented HK$2,961,566. Net cost per quality adjusted life year gained was HK$73,218 and HK$65,280 non-discounted, respectively using the two alternative models.
Conclusions:
The results of this study can assist in prioritising the use of health care resources in Hong Kong but should be considered alongside the benefits and costs of alternative interventions for coronary heart disease.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients